POINT Biopharma Global Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From POINT Biopharma Global Inc.
The major’s radioligand therapy has succeeded in an earlier line of prostate cancer therapy that presents a large market opportunity, but some observers are keen to see full data before raising their sales projections.
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.
With the successful launch of Novartis’ Pluvicto and Lutathera, more firms are developing radioligands in the hopes of mitigating side effects and addressing unmet needs in cancer.
- Radiopharmaceuticals, Contrast Agents